Cargando…
The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review
There is a vital role of B cells in the pathogenesis of Systemic Lupus Erythematosus (SLE). Belimumab (Bel), an inhibitor of B cell activating factor (BAFF), and Rituximab (RTX), a monoclonal antibody targeting Cd20 antigen, have been used to manage systemic lupus. Several randomized controlled tria...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360028/ https://www.ncbi.nlm.nih.gov/pubmed/37485087 http://dx.doi.org/10.7759/cureus.40719 |
_version_ | 1785076012595281920 |
---|---|
author | Abid, Naushad Manaye, Sara Naushad, Hamzah Cheran, Kaaviya Murthy, Chinmayee Bornemann, Elisa A Kamma, Hari Krishna Alabbas, Mohammad Elashahab, Mohammed |
author_facet | Abid, Naushad Manaye, Sara Naushad, Hamzah Cheran, Kaaviya Murthy, Chinmayee Bornemann, Elisa A Kamma, Hari Krishna Alabbas, Mohammad Elashahab, Mohammed |
author_sort | Abid, Naushad |
collection | PubMed |
description | There is a vital role of B cells in the pathogenesis of Systemic Lupus Erythematosus (SLE). Belimumab (Bel), an inhibitor of B cell activating factor (BAFF), and Rituximab (RTX), a monoclonal antibody targeting Cd20 antigen, have been used to manage systemic lupus. Several randomized controlled trials (RCTs) have evaluated these two agents' clinical efficacy and safety in different manifestations of SLE. This study aims to review the randomized control trials involving these two agents systematically and to explain if any disparity is noticed in the primary and secondary outcomes between these two agents. This study is done according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. After applying the inclusion criteria and quality assessment by independent reviewers and co-authors, relevant papers were identified, and data were extracted. The results have shown that RCTs involving Belimumab achieved primary endpoints; however, targeted endpoints were not achieved in studies involving Rituximab. It is concluded that despite the conflicting results obtained in clinical trials, both are effective in systemic lupus, as indicated in real-world clinical experience. However, better-designed multicenter studies evaluating these B-cell-targeting drugs are needed. |
format | Online Article Text |
id | pubmed-10360028 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-103600282023-07-22 The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review Abid, Naushad Manaye, Sara Naushad, Hamzah Cheran, Kaaviya Murthy, Chinmayee Bornemann, Elisa A Kamma, Hari Krishna Alabbas, Mohammad Elashahab, Mohammed Cureus Allergy/Immunology There is a vital role of B cells in the pathogenesis of Systemic Lupus Erythematosus (SLE). Belimumab (Bel), an inhibitor of B cell activating factor (BAFF), and Rituximab (RTX), a monoclonal antibody targeting Cd20 antigen, have been used to manage systemic lupus. Several randomized controlled trials (RCTs) have evaluated these two agents' clinical efficacy and safety in different manifestations of SLE. This study aims to review the randomized control trials involving these two agents systematically and to explain if any disparity is noticed in the primary and secondary outcomes between these two agents. This study is done according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. After applying the inclusion criteria and quality assessment by independent reviewers and co-authors, relevant papers were identified, and data were extracted. The results have shown that RCTs involving Belimumab achieved primary endpoints; however, targeted endpoints were not achieved in studies involving Rituximab. It is concluded that despite the conflicting results obtained in clinical trials, both are effective in systemic lupus, as indicated in real-world clinical experience. However, better-designed multicenter studies evaluating these B-cell-targeting drugs are needed. Cureus 2023-06-21 /pmc/articles/PMC10360028/ /pubmed/37485087 http://dx.doi.org/10.7759/cureus.40719 Text en Copyright © 2023, Abid et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Allergy/Immunology Abid, Naushad Manaye, Sara Naushad, Hamzah Cheran, Kaaviya Murthy, Chinmayee Bornemann, Elisa A Kamma, Hari Krishna Alabbas, Mohammad Elashahab, Mohammed The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review |
title | The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review |
title_full | The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review |
title_fullStr | The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review |
title_full_unstemmed | The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review |
title_short | The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review |
title_sort | safety and efficacy of rituximab and belimumab in systemic lupus erythematosus: a systematic review |
topic | Allergy/Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10360028/ https://www.ncbi.nlm.nih.gov/pubmed/37485087 http://dx.doi.org/10.7759/cureus.40719 |
work_keys_str_mv | AT abidnaushad thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT manayesara thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT naushadhamzah thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT cherankaaviya thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT murthychinmayee thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT bornemannelisaa thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT kammaharikrishna thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT alabbasmohammad thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT elashahabmohammed thesafetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT abidnaushad safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT manayesara safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT naushadhamzah safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT cherankaaviya safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT murthychinmayee safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT bornemannelisaa safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT kammaharikrishna safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT alabbasmohammad safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview AT elashahabmohammed safetyandefficacyofrituximabandbelimumabinsystemiclupuserythematosusasystematicreview |